TILS.L Regulatory News (TILS)

26 Apr 2005 12:39

ReGen Therapeutics PLC27 April 2005 ReGen Therapeutics Plc 27 April 2005 AGM Statement ReGen Therapeutics Plc ("ReGen" or the "Company"), a company whose business isin developing treatments for Alzheimer's disease, human and veterinarynutraceuticals and contract research held its Annual General Meeting today. Atthe meeting the company also announced that it is committing resources toParkinson's disease as a result of the study outlined below. Percy Lomax Chairman and Chief Executive of ReGen commented: 'There have beenfavourable developments in the Company's business since its Annual CityPresentation in December 2004. In particular I am pleased to report that we areengaged in a number of ongoing negotiations with potential licensing partners.The Company continues to believe that a partnering deal in nutraceuticals ispossible in 2005 with revenue from sales in 2006 and a partnering deal inpharmaceuticals in 2007. From a science perspective I am pleased to announceearly results from the studies into Colostrinin(TM) derived peptides as detailedin the following paragraphs: Colostrinin(TM) and a synthetic homolog of Colostrinin(TM) -derived peptide showneuroprotection in a cell line model of Parkinson's disease. An in-vitro study has shown that pre-treatment with Colostrinin(TM) and asynthetic version of a peptide shown to occur naturally in Colostrinin(TM) canprotect cells of the kind that are depleted in Parkinson's disease from damageby a chemical known to be selectively toxic to them. Commenting on the findings, Professor Peter Jenner, the Chief Scientific Officerof Proximagen Neuroscience Plc* that conducted the study on ReGen's behalf said: 'The initial data from this study suggests that Colostrinin(TM) and peptideswithin it may protect dopaminergic neurones against degeneration. As such, wehave recommended to ReGen that Colostrinin(TM) and the peptides are nowevaluated for neuroprotective effects in a predictive functional model ofParkinson's disease'. Percy Lomax commented: 'This is a very encouraging finding. We believe that notonly does it confirm the general neuroprotective effect of Colostrinin(TM) thatwe are now developing as a nutraceutical, but it shows that a second peptide,naturally present in this complex, has activity in its own right. Anotherpeptide has previously been shown to improve memory function in an in-vivo studyin aged rats**. As the peptides used in both cases were synthetic versions, thisoffers the prospect of developing these, or small molecular weight substancesbased upon them or other peptides within Colostrinin(TM), as classicalpharmaceuticals for use in perhaps more than one disease'. Revenue generation The Company remains firmly focussed on developing its revenue producing businessand is pursuing a number of opportunities in this area. In particular it seesthe contract research area as a potential path for expansion following on fromits acquisition of Guildford Clinical Pharmacology Unit Limited. *Proximagen Neuroscience plc, the publicly traded (PRX-AiM) drug discovery anddevelopment company that is focused on neurodegenerative disease, was founded byProfessor Peter Jenner in conjunction with King(1)s College in November 2003 todraw upon over 25 years of pre-eminent neurodegenerative research. ** P Popik et al, Behavioural Brain Research 118 (2001) 201-208 For further information, please contact: Andrew Marshall Marshall Robinson Roe0207 960 6007 This information is provided by RNS The company news service from the London Stock Exchange